Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene

Archives of Oral Biology

Volumn 55, Issue 1, 2010, Pages 52-59

  LUVIZUTO, Eloá Rodrigues ^a   QUEIROZ, Thallita Pereira ^a   DIAS, Sheila Mônica Damásio ^a   OKAMOTO, Tetuo ^a   DORNELLES, Rita Cássia Menegati ^a   GARCIA Jr , Idelmo Rangel ^a   OKAMOTO, Roberta ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alveolar process; Estradiol; Osteoblasts; Osteoprotegerin; Ovariectomy; Raloxifene; RANKL

Indexed keywords

ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; DRUG EFFECT; FEMALE; INCISOR; JAW; METABOLISM; OVARIECTOMY; RAT; TOOTH EXTRACTION; WISTAR RAT; WOUND HEALING;

ALVEOLAR PROCESS; ANALYSIS OF VARIANCE; ANIMALS; ESTROGENS; FEMALE; INCISOR; OSTEOPROTEGERIN; OVARIECTOMY; RALOXIFENE; RANK LIGAND; RATS; RATS, WISTAR; TOOTH EXTRACTION; WOUND HEALING;

RATTUS; RATTUS NORVEGICUS;

EID: 72649098090     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2009.11.001     Document Type: Article

References (49)

1. Kwan Tat S., Padrines M., Théoleyre S., Heymann, and Fortun Y. Il-6 RANKL TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 1 (2004) 49-60
2. Raisz L.G., and Rodan G.A. Embryology and cellular biology of bone. In: Avioli L.V., and Krane S.M. (Eds). Metabolic bone disease and clinically related disorders (1998), Academic Press, New York p. 1-22
3. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 2 (2000) 115-137
4. Liu C.C., and Howard G.A. Bone-cell changes in estrogen-induced bone-mass increase in mice: dissociation of osteoclasts from bone surfaces. Anat Rec 229 2 (1991) 240-250
5. Tanaka M., Ejiri S., Toyooka E., Kohno S., and Ozawa H. Effects of ovariectomy on trabecular structures of rat alveolar bone. J Periodontal Res 37 2 (2002) 161-165
6. Duarte M.P., de Assis D.R., Casati M.Z., Sallum A.W., Sallum E.A., and Nociti Jr. F.H. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol 75 9 (2004) 1196-1202
7. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 5484 (2000) 1508-1514
8. Burg M.A., Fraser K., Gui S., Grant K., Kosch S.G., Nierenberg B., et al. Treatment of menopausal symptoms in family medicine settings following the Women's Health Initiative findings. J Am Board Fam Med 19 2 (2006) 122-131
9. Regan M.M., Emond S.K., Attardo M.J., Parker R.A., and Greenspan S.L. Why do older women discontinue hormone replacement therapy?. J Womens Health Gend Based Med 10 4 (2001) 343-350
10. Ettinger B., Black D.M., Mitlak B.H., Knicherbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282 7 (1999) 637-645
11. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.Á., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281 23 (1999) 2189-2197
12. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287 7 (2002) 847-857
13. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 2 (1998) 165-176
14. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 7 (1999) 3540-3545
15. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
16. Okamoto T., and Russo M.C. Wound healing following tooth extraction: histochemical study in rats. Rev Fac Odontol Araçatuba 2 2 (1973) 153-169
17. Carvalho ACP, Okamoto T. Cirurgia bucal: fundamentos experimentais aplicados a clínica. São Paulo: Panamericana; 1987.
18. National Research Council. Guide for the care and use of laboratory animals. DHHS publication no. (NIH) 85-23 (rev.). Department of Health and Human Services, NRC, Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources; 1985.
19. Hsieh Y.D., Devlin H., and Roberts C. Early alveolar ridge osteogenesis following tooth extraction in the rat. Arch Oral Biol 39 5 (1994) 425-428
20. Geddes A. Animal models of bone disease. In: Principles of bone biology. San Diego: Academic Press; 1996. p. 1343.
21. Fernández-García D., Muñoz-Torrez M., Mezquita-Raya P., de la Hiquera M., Alonso G., Reyes-García R., et al. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest 31 5 (2008) 416-421
22. Yasui T., Uemura H., Hyodo S., Yamada M., Yamamoto S., Maegawa M., et al. Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women. Atherosclerosis 204 2 (2009) 471-475
23. Punyadeera C., Kamps R., Defrère S., Dijcks F., de Goeij A., Ederveen A., et al. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. J Steroid Biochem Mol Biol 112 1-3 (2008) 102-109
24. Kim Y.S., Koh J.M., Lee Y.S., Kim B.J., Lee S.H., Lee K.U., et al. Increased circulating heat shock protein 60 induced by menopause, stimulates apoptosis of osteoblast-lineage cells via up-regulation of toll-like receptors. Bone 45 1 (2009) 68-76
25. Duarte P.M., Gonçalves P.F., Sallum A.W., Sallum E.A., Casati M.Z., and Nociti Jr. F.H. Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodontal Res 39 2 (2004) 107-110
26. Duarte P.M., Gonçalves P.F., Casati M.Z., de Toledo S., Sallum E.A., and Nociti Jr. F.H. Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: a histometric study in rats. J Periodontal Res 41 6 (2006) 541-546
27. Sakakura C.E., Giro G., Gonçalves D., Pereira R.M., Orrico S.R., and Marcantonio Jr. E. Radiographic assessment of bone density around integrated titanium implants after ovariectomy in rats. Clin Oral Implants Res 17 2 (2006) 134-138
28. Elovic R.P., Hipp J.A., and Hayes W.C. Maxillary molar extraction causes increased bone loss in the mandible of ovariectomized rats. J Bone Miner Res 10 7 (1995) 1087-1093
29. Shimizu M., Furuya R., Kawawa T., and Sasaki T. Bone wound healing after maxillary molar extraction in ovariectomized aged rats: quantitative backscattered electron image analysis. Anat Rec 259 1 (2000) 76-85
30. Hsieh Y.D., Devlin H., and McCord F. The effect of ovariectomy on the healing tooth socket of the rat. Arch Oral Biol 40 6 (1995) 529-531
31. Teófilo J.M., Brentegani L.G., and Lamano-Carvalho T.L. Bone healing in osteoporotic female rats following intra-alveolar grafting of bioactive glass. Arch Oral Biol 49 9 (2004) 755-762
32. Rogers A., and Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 11 (2005) 6323-6331
33. Boyce B.F., and Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9 Suppl 1 (2007) S1
34. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A. Current challenges in BMP delivery. Biotechnol Lett 2009 [Epub ahead of print].
35. Young S., Patel Z.S., Kretlow J.D., Murphy M.B., Mountziaris P.M., Baggett L.S., et al. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A 15 9 (2009) 2347-2362
36. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 9 (1998) 1260-1268
37. Quinn J.M., Elliott J., Gillespie M.T., and Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139 10 (1998) 4424-4427
38. Yasuda E, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602.
39. Hofbauer L.C., and Heufelder A.E. Clinical review 114: hot topic The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85 7 (2000) 2355-2363
40. Eghbali-Fatourechi G., Klosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early posmenopausal women. J Clin Invest 111 8 (2003) 1221-1230
41. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 6759 (1999) 304-309
42. Teng Y.T., Nguyen H., Gao X., Kong Y.Y., Gorczynski R.M., Singh B., et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 106 6 (2000) R59-R67
43. Price P.A., June H.H., Buckley J.R., and Williamson Mk. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 10 (2001) 1610-1616
44. Cheng X., Kinosaki M., Takami M., Choi Y., Zhang H., and Murali R. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem 279 9 (2004) 8269-8277
45. Shevde N.K., Bendixen A.C., Dienger K.M., and Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97 14 (2000) 7829-7834
46. Hofbauer L.C., Khosla S., Dunstan C.R., Lancey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 9 (1999) 4367-4370
47. Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. Menopause 2009 [Epub ahead of print].
48. Kobayashi Y., Hashimoto F., Miyamoto H., Kanaoka K., Miyazaki-Kawashita Y., Nakashima T., et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J Bone Miner Res 15 10 (2000) 1924-1934
49. Onyia J.E., Galvin R.J., Ma Y.L., Halladay D.L., Miles R.R., Yang X., et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 309 1 (2004) 369-379